Prophylactic Peripheral Laser and Fluorescein Angiography After Bevacizumab for Retinopathy of Prematurity

González, Josué M.; Snyder, Laura; Blair, Michael P.; Rohr, Ashley; Shapiro, Michael J.; Greenwald, Mark J.

doi:10.1097/iae.0000000000001581

Cited by 82 publications

(38 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Since 2006, the safety of FA application in neonates has been described [22]. Several studies then reported the diagnosis, treatment, and follow-up with FA in ROP management [17,20,23,24]. e present study focuses on the angiographic findings after primary treatment of IVC or IVR and tries to better describe the vasculature outcomes of ROP after anti-VEGF treatment.…”

Section: Discussionmentioning

confidence: 99%

“…e FA exam lasted about 5 minutes for each infant in our center. e primary outcomes studied were FA photogram data collected including the peripheral avascular zone, vascular fluorescein leakage, vascular blunting, vascular loops, vascular dilatation, arteriovenous shunt, and capillary dropout [20]. e avascular zone in the present study was defined as a distance of greater than 2 DD from the ora to the vascular terminus.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Fluorescein Angiographic Findings of Peripheral Retinal Vasculature after Intravitreal Conbercept versus Ranibizumab for Retinopathy of Prematurity

Jin

Yin

Gui

et al. 2019

Journal of Ophthalmology

View full text Add to dashboard Cite

Purpose. To evaluate angiographic findings of peripheral retina vasculature in retinopathy of prematurity (ROP) neonates who received intravitreal conbercept (IVC) or ranibizumab (IVR). Methods. Fluorescein angiography (FA) findings were retrospectively evaluated for ROP neonates who received IVC or IVR. Outcome measures included peripheral avascular zone, vascular leakage, vascular blunting, vascular loops, vascular dilatation, arteriovenous shunt, and capillary dropout. Results. Fifty-four eyes (28 patients) with ROP were included. Twenty-nine eyes (15 patients) received IVC, and 25 eyes (13 patients) received IVR. For infants of the IVC group, the mean gestational age, birth weight, and postmenstrual age (PMA) at the initial treatment were 28.96 ± 2.36 weeks, 1168.8 ± 344.5 g, and 41.22 ± 4.39 weeks, respectively. For the IVR group, they were 28.83 ± 2.34 weeks, 1255.0 ± 356.9 g, and 39.42 ± 2.77 weeks, respectively (P=0.817, 0.522, and 0.075). For the IVC group, FA performed at 71.29–115.43 weeks PMA showed 96.55% of eyes had avascular zone; vascular leakage was found in 24.14% eyes; vascular blunting, vascular dilation, vascular loops, arteriovenous shunt, and capillary dropout were found in 96.55%, 72.41%, 79.31%, 48.28%, and 68.97% eyes, respectively. For the IVR group, FA performed at 65.57–133.71 weeks PMA showed 92.0% of eyes had avascular zone; vascular leakage was found in 40.0% eyes; vascular blunting, dilatation, loops, arteriovenous shunt, and capillary dropout were found in 100%, 60.0%, 64.0%, 36.0%, and 68.0% eyes, respectively. Conclusion. No significant difference can be observed between the IVC group and IVR group for peripheral vascular structure anomalies with FA evidence. FA studies should be considered to assess the status of the peripheral retinal vasculature to determine therapeutic outcomes and potential functional outcomes.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Fluorescein Angiographic Findings of Peripheral Retinal Vasculature after Intravitreal Conbercept versus Ranibizumab for Retinopathy of Prematurity

Jin

Yin

Gui

et al. 2019

Journal of Ophthalmology

View full text Add to dashboard Cite

show abstract

“…Moreover, when recurrences occur, their locations and patterns may be altered compared with the original pathology [ 9 , 13 , 15 ]. Several efforts have been made to combine laser photocoagulation and IVB to minimise retinal damage and maximise treatment efficacy, including studies combining IVB therapy with Zone I or posterior pole-sparing laser treatment [ 10 , 16 , 17 ]. We performed eccentric laser photocoagulation on the avascular area sparing the temporal Zone II area and injected bevacizumab simultaneously.…”

Section: Discussionmentioning

confidence: 99%

“…When IVB was combined with Zone I-sparing laser treatment, neither reactivation nor retinal detachment was reported for 83.6 weeks PMA [ 21 ]. Treatment of ROP with bevacizumab followed by prophylactic laser therapy also showed no reactivation for 125 weeks PMA [ 17 ]. Taken together with our findings, these results demonstrate that combining laser therapy with IVB treatment is a safe way to prevent delayed reactivation of ROP.…”

Section: Discussionmentioning

confidence: 99%

Functional and Structural Outcomes of Temporal Zone II-Sparing Laser Photocoagulation Combined with Intravitreal Bevacizumab in Retinopathy of Prematurity

Seo

Lee

2018

Journal of Ophthalmology

View full text Add to dashboard Cite

Background/Aim The aim of the study was to investigate the outcomes of temporal Zone II-sparing laser photocoagulation combined with intravitreal bevacizumab (IVB) in patients with Type 1 retinopathy of prematurity (ROP) in Zone I. Methods Medical records of 74 eyes of 37 infants were analysed. Only infants with Type 1 ROP in Zone I were included. Thirty-two eyes were treated with temporal-sparing laser + IVB. Both Zone I and temporal Zone II were spared to minimise potential visual field loss. Forty-two eyes were treated with laser alone conventionally. Early treatment outcomes, late complications, and refractive errors were analysed. Results The mean gestational age and birth weight of the enrolled patients were 25.7 ± 2.5 weeks and 798.8 ± 440.2 g, respectively. In the combined treatment group, plus sign regression was achieved faster (12.1 ± 6.2 days vs. 25.6 ± 21.3 days, p=0.011) and retreatment was required less (0% vs. 23.8%, p=0.004) than in the laser-alone group. Retinal/preretinal haemorrhages occurred more often in the laser-alone group (42.9% vs. 9.4%, p=0.002). Normal development of temporal retinal vessels was also observed in twelve eyes in the combined treatment group. No differences in late complications or refractive errors were observed between the groups. Conclusion Temporal Zone II-sparing laser treatment combined with IVB showed good early treatment outcome and temporal retinal vessels development.

show abstract

“…We have not seen a recurrence after prophylactic laser. 7 Centers without FA capabilities could treat under anesthesia or sedation, based on careful examination attentive to patterns of reactivation. Alternatively, infants could be referred to centers with access to FA.…”

Section: Reply To Letter To the Editor: Very Late Reactivation Of Retmentioning

confidence: 99%

Letter to the Editor: Very Late Reactivation of Retinopathy of Prematurity After Monotherapy With Intravitreal Bevacizumab

Mataftsi¹,

Koulali²,

Papageorgiou³

et al. 2017

Ophthalmic Surg Lasers Imaging Retina

View full text Add to dashboard Cite

Prophylactic Peripheral Laser and Fluorescein Angiography After Bevacizumab for Retinopathy of Prematurity

Abstract: In our study, bevacizumab-treated eyes with APROP have a higher likelihood of recurrence and larger area of persistent nonperfusion than in eyes with CROP. Treatment of ROP with bevacizumab followed by prophylactic laser has a low rate of unfavorable structural outcome.

Cited by 82 publications

References 45 publications

Fluorescein Angiographic Findings of Peripheral Retinal Vasculature after Intravitreal Conbercept versus Ranibizumab for Retinopathy of Prematurity

Fluorescein Angiographic Findings of Peripheral Retinal Vasculature after Intravitreal Conbercept versus Ranibizumab for Retinopathy of Prematurity

Functional and Structural Outcomes of Temporal Zone II-Sparing Laser Photocoagulation Combined with Intravitreal Bevacizumab in Retinopathy of Prematurity

Letter to the Editor: Very Late Reactivation of Retinopathy of Prematurity After Monotherapy With Intravitreal Bevacizumab

Contact Info

Product

Resources

About